Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

Neurology

Volumn 72, Issue 5, 2009, Pages 396-401

  Stuve O ^a,b,c,d   Cravens, P D ^b   Frohman, E M ^b   Phillips, J T ^e   Remington, G M ^b   Von Geldern, G ^d   Cepok, S ^d   Singh, M P ^b   Cohen Tervaert, J W ^f   De Baets, M ^f   MacManus, D ^g   Miller, D H ^g   Radu E W ^h   Cameron, E M ^b,c   Monson, N L ^b,c   Zhang, S ^c   Kim, R ⁱ   Hemmer, B ^j   Racke, M K ^k  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Multiple Sclerosis Center at Texas Neurology   (United States)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ BIOGEN   (United States)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; BLOOD; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DISABILITY; DRUG EFFECT; HOSPITALIZATION; IMMUNOLOGY; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 61549088471     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000327341.89587.76     Document Type: Article

References (13)

1. Stuve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007; 13:79-95.
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
4. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.
5. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353: 375-381.
6. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368.
7. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747.
8. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4/CD8 T cells ratios in cerebrospinal fluid of natalizumabtreated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-1387.
9. Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin Chem 1995; 41:256-263.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
11. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
12. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008;70:1150-1151.
13. Stuve O, Marra CM, Cravens PD, et al. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 2007; 64:169-176.